Zymeworks Reports Phase 1 ZW191 Data in Ovarian Cancer
Phase 1 randomized data showed a 64.5% cORR at 6.4 mg/kg versus 55.3% at 9.6 mg/kg, with fewer grade ≥3 adverse events at 6.4 mg/kg. Responses spanned high to low or negative FRα expression.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.